Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Metoprolol
Drug ID BADD_D01445
Description Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative.[T274] To this date, it is one of the preferred beta-blockers in general clinical guidelines and it is widely prescribed in the Netherlands, New Zealand, and the US.[A175162] Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978.[L5527]
Indications and Usage Metoprolol is indicated for the treatment of angina, heart failure, myocardial infarction, atrial fibrillation, atrial flutter and hypertension.[A175141] Some off-label uses of metoprolol include supraventricular tachycardia and thyroid storm.[A175141] All the indications of metoprolol are part of cardiovascular diseases. These conditions correspond to a number of diseases that involve the function of the heart and blood vessels. The underlying causes of these conditions are variable and can be due to genetic disposition, lifestyle decisions such as smoking, obesity, diet, and lack of exercise, and comorbidity with other conditions such as diabetes. The cardiovascular diseases are the leading cause of death on a global scale.[L5533]
Marketing Status approved; investigational
ATC Code C07AB02
DrugBank ID DB00264
KEGG ID D02358
MeSH ID D008790
PubChem ID 4171
TTD Drug ID D0I2MK
NDC Product Code 70518-3506; 46708-292; 62207-970; 62332-113; 46708-290; 0615-8422; 0615-8423; 46708-291; 62332-114; 62332-112; 71205-003; 0615-8421; 65977-0117
UNII GEB06NHM23
Synonyms Metoprolol | Toprol | Betaloc | Betaloc-Astra | Betaloc Astra | Betalok | CGP-2175 | CGP 2175 | CGP2175 | H 93-26 | H 93 26 | H 9326 | Metoprolol Tartrate | Seloken | Spesicor | Spesikor | Metoprolol Succinate | Metoprolol CR-XL | Metoprolol CR XL | Toprol-XL | Toprol XL | Beloc-Duriles | Beloc Duriles | Lopressor
Chemical Information
Molecular Formula C15H25NO3
CAS Registry Number 51384-51-1
SMILES CC(C)NCC(COC1=CC=C(C=C1)CCOC)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Arterial insufficiency24.04.02.005--Not Available
Lichenoid keratosis23.01.01.0040.000007%Not Available
Complex regional pain syndrome17.02.07.010; 12.01.12.0040.000007%Not Available
Neuropsychological test abnormal13.07.06.001--Not Available
Aortic arteriosclerosis24.04.01.004--Not Available
Suicidal behaviour19.12.01.0060.000007%Not Available
Uterine hyperstimulation21.07.03.006; 18.07.02.0080.000007%Not Available
Treatment failure08.06.01.0170.000061%Not Available
Organising pneumonia22.01.02.0080.000010%Not Available
Adverse reaction08.06.01.0180.000007%Not Available
Low birth weight baby18.04.02.0030.000087%Not Available
Cholestatic liver injury09.01.07.0160.000007%Not Available
Anorectal discomfort07.03.03.0030.000023%Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.008--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Kounis syndrome24.04.04.020; 10.01.03.037; 02.02.02.0200.000047%Not Available
Acute kidney injury20.01.03.0160.000107%
Atrioventricular dissociation02.03.01.0120.000007%Not Available
Foetal growth restriction18.03.01.0020.000057%
Drug-induced liver injury09.01.07.023; 12.03.01.0440.000053%Not Available
Substance-induced psychotic disorder19.03.01.007; 12.03.01.0530.000060%Not Available
Foetal heart rate deceleration abnormality18.03.02.012; 02.03.02.0220.000010%Not Available
Encapsulating peritoneal sclerosis07.07.03.0040.000020%Not Available
Mouth swelling23.04.01.020; 10.01.05.020; 07.05.04.0070.000015%Not Available
Infantile vomiting07.01.07.010; 18.04.11.0040.000010%Not Available
Sinus node dysfunction02.03.03.0170.000040%
Intestinal angioedema23.04.01.019; 10.01.05.019; 07.08.03.0120.000007%Not Available
Frustration tolerance decreased19.04.02.016--Not Available
Apnoeic attack22.02.01.027; 17.02.05.0510.000007%Not Available
Concomitant disease aggravated08.01.03.0630.000007%Not Available
The 15th Page    First    Pre   15 16 17    Next   Last    Total 17 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene